Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cyclacel Pharmaceuticals advances Phase II study with promising results and financial boost

Cyclacel Pharmaceuticals made significant progress in Q1 2024 with financing, study advancements, and expense management.
While facing financial challenges and study enrollment timelines, the company remains focused on key milestones and opportunities.
The company's strengths lie in promising study results, solid cash position, and proactive approach to clinical development.
Overall, Cyclacel Pharmaceuticals is poised for growth and value creation in 2024 through strategic advancements.

Cyclacel Pharmaceuticals progresses with fadra, poised for oncology market growth

Cyclacel's fadra program is showing clinical promise and cost efficiency, supported by a stable financial position.
Clear communication of enrollment targets and data disclosure timelines is crucial for maintaining investor confidence.
Optimism for upcoming milestones and engagement opportunities position Cyclacel well for potential growth in the oncology market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Cyclacel Pharmaceuticals Inc 6 % Conv Pfd Shs

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript

BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on Wednesday, November 11, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. 

Cyclacel Pharmaceuticals to Release Third Quarter Financial Results

A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib

Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum, M.D. as Senior Vice President & Chief Medical Officer (CMO). Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical trial design and patient care. He has management experience in both academic research and clinical and pharmaceutical settings. As CMO, he will be responsible for advancing Cyclacel's pipeline and will lead clinical strategy, patient safety, and medical affairs.

Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

BERKELEY HEIGHTS, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company is scheduled to participate in a virtual presentation and fireside chat at the October 2020 Lytham Partners Virtual Investor Growth Conference on Thursday, October 8, 2020 at 8:00am ET.

Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference

BERKELEY HEIGHTS, N.J., Sept.  21, 2020  (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data with Cyclacel's CDK2/9 inhibitor fadraciclib has been selected for an oral presentation at the 32nd EORTC-NCI-AACR (ENA) Symposium 2020 being held virtually on October 24 – 25, 2020. The data is from an ongoing Phase 1 study of fadraciclib as a single agent in patients with advanced solid tumors.

Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2020 Results - Earnings Call Transcript

- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - - Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -

Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results on Wednesday, August 12, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. 

Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.

Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against

Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2020 Results - Earnings Call Transcript

- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET -

Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., April  24, 2020  (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced public offering of (i) 4,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) common warrants to purchase up to 4,000,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant, was sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $5.00 per share and accompanying common warrant, and/or $4.999 per pre-funded warrant and accompanying common warrant. For each pre-funded warrant the Company sold, the number of shares of common stock the Company offered was decreased on a one-for-one basis. The common warrants are immediately exercisable at a price of $5.00 per share of common stock and will expire five years from the date of issuance. The shares of common stock and/or the pre-funded warrants, and the accompanying common warrants, were purchased together in the offering, but were issued separately and became immediately separable upon issuance. After deducting placement agent fees and other offering expenses payable by the Company, total net proceeds of the public offering are approximately $18.4 million. 

Cyclacel Announces Closing of $20 Million Public Offering

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) shares were crushed on Tuesday after the company announced the pricing of a secondary offering.

Cyclacel Pharmaceuticals Investors Should Be Furious After This Move

BERKELEY HEIGHTS, N.J., April  21, 2020  (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of a public offering with expected total gross proceeds of approximately $20 million, before deducting placement agent fees and other offering expenses payable by the Company. 

CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING

Shares of nanocap biopharma Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) were ripping higher Monday following the announcement of a partnership to study two of its drugs to treat complications arising from COVID-19.

Nano-Cap Cyclacel Rockets Higher On Launch Of Study For Coronavirus Inflammation

-Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury- -Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury-

Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease

BERKELEY HEIGHTS, N.J., April  14, 2020  (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that effective at 5:00 p.m., Eastern Time, on April 14, 2020 (the “Effective Time”), the Company will effect a one-for-twenty reverse stock split of its outstanding common stock.  The reverse stock split, which was unanimously approved by the Company’s Board of Directors, was approved by its stockholders at a Special Meeting of Stockholders held on October 28, 2019. The Company’s common stock will open for trading on The NASDAQ Capital Market on April 15, 2020 on a post-split basis. 

Cyclacel Announces Reverse Stock Split

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2019 Results - Earnings Call Transcript

We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?

CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies

Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2019 Results - Earnings Call Transcript

BERKELEY HEIGHTS, N.J., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24 at the Sofitel Hotel, New York. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and its progress in key programs.

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept.  09, 2019  (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral formulation of CYC065, a CDK2/9 inhibitor, in part 3 of a Phase 1 study (CYC065-01) which is evaluating single agent CYC065 in patients with advanced solid cancers. Parts 1 and 2 of the study are evaluating CYC065 administered as an intravenous infusion.

News for Cyclacel Pharmaceuticals Stock (CYCC)